Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Chantale Bernatchez et al.|Cancer Discovery|2020Cited by 239
Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.Chantale Bernatchez, Adi Diab, Cara Haymaker et al.|Journal of Clinical Oncology|2017Cited by 23
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.Michael E. Hurwitz, Adi Diab, Daniel C. Cho et al.|Journal of Clinical Oncology|2019Cited by 22
Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumabJoshua Veatch, Stanley R. Riddell, Naina Singhi et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 9
CD-19-1510R1_Supplementary_Appendix.docx from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Nizar M. Tannir et al.|Unknown|2023Cited by 0